Kadmon to Present Interim Data on KD025 in Chronic Graft-Versus-Host Disease (cGVHD) at R&D Day
June 23 2017 - 9:00AM
Business Wire
-- Event on July 11 in New York City with Live
Webcast --
Kadmon Holdings, Inc. (NYSE: KDMN) (“Kadmon” or the “Company”)
will present interim data from its ongoing Phase 2 clinical trial
of KD025, the Company’s lead ROCK2 inhibitor, in previously treated
patients with chronic graft-versus-host disease (“cGVHD”). The data
will be presented at Kadmon’s Research and Development (“R&D”)
Day in New York City on Tuesday, July 11, 2017, from 8:45 a.m. to
11:00 a.m. ET.
The R&D Day will feature presentations by key opinion
leaders, including Bruce Blazar, M.D., Regents Professor in the
Department of Pediatrics, Chief of the Pediatric Blood and Marrow
Transplantation Program and Vice Dean for Clinical Investigation at
the School of Medicine at the University of Minnesota, Minneapolis,
MN. Dr. Blazar will share the findings of his preclinical research
on KD025 in cGVHD. Also presenting is Amandeep Salhotra, M.D.,
Assistant Professor, Hematology and Hematopoietic Cell
Transplantation at City of Hope, Duarte, CA. Dr. Salhotra will
present interim data from the first cohort (KD025 200 mg QD) of the
ongoing cGVHD trial.
Kadmon’s executive management team, led by Harlan W. Waksal,
M.D., President and Chief Executive Officer, will provide an update
on KD025 as well as the Company’s ROCK inhibitor platform. KD025 is
being studied in three ongoing clinical trials in autoimmune and
fibrotic diseases: A placebo-controlled Phase 2 clinical trial in
moderate to severe psoriasis, an open-label Phase 2 clinical trial
in idiopathic pulmonary fibrosis and an open-label Phase 2 clinical
trial in cGVHD.
The R&D Day is intended for institutional investors and
sell-side analysts only. For more information, please email Ellen
Tremaine, Manager, Investor Relations at Kadmon, at
ellen.tremaine@kadmon.com. A live and archived webcast of the
event, with slides, will be available on the Investors section of
the Kadmon website at www.kadmon.com.
About Kadmon Holdings, Inc.
Kadmon Holdings, Inc. is a fully integrated biopharmaceutical
company focused on developing innovative products for significant
unmet medical needs. We have a diversified product pipeline in
autoimmune and fibrotic diseases, oncology and genetic
diseases.
Safe Harbor Statement
This press release contains forward-looking statements. Such
statements may be preceded by the words “may,” “will,” “should,”
“expects,” “plans,” “anticipates,” “could,” “intends,” “targets,”
“projects,” “contemplates,” “believes,” “estimates,” “predicts,”
“potential” or “continue” or the negative of these terms or other
similar expressions. Forward-looking statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. We believe that these factors include, but are not
limited to, (i) the initiation, timing, progress and results of our
preclinical studies and clinical trials, and our research and
development programs; (ii) our ability to advance product
candidates into, and successfully complete, clinical trials; (iii)
our reliance on the success of our product candidates; (iv) the
timing or likelihood of regulatory filings and approvals; (v) our
ability to expand our sales and marketing capabilities; (vi) the
commercialization of our product candidates, if approved; (vii) the
pricing and reimbursement of our product candidates, if approved;
(viii) the implementation of our business model, strategic plans
for our business, product candidates and technology; (ix) the scope
of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and
technology; (x) our ability to operate our business without
infringing the intellectual property rights and proprietary
technology of third parties; (xi) costs associated with defending
intellectual property infringement, product liability and other
claims; (xii) regulatory developments in the United States, Europe
and other jurisdictions; (xiii) estimates of our expenses, future
revenues, capital requirements and our needs for additional
financing; (xiv) the potential benefits of strategic collaboration
agreements and our ability to enter into strategic arrangements;
(xv) our ability to maintain and establish collaborations or obtain
additional grant funding; (xvi) the rate and degree of market
acceptance of our product candidates; (xvii) developments relating
to our competitors and our industry, including competing therapies;
(xviii) our ability to effectively manage our anticipated growth;
(xix) our ability to attract and retain qualified employees and key
personnel; (xx) our ability to achieve cost savings and other
benefits from our efforts to streamline our operations and to not
harm our business with such efforts; and (xxi) the use of proceeds
from our recent private placement. More detailed information about
Kadmon and the risk factors that may affect the realization of
forward-looking statements is set forth in the Company's filings
with the U.S. Securities and Exchange Commission (SEC), including
the Company's Quarterly Report on Form 10-Q filed pursuant to
Section 13 of the Securities Exchange Act of 1934, as amended, with
the SEC on May 15, 2017. Investors and security holders are urged
to read these documents free of charge on the SEC's web site at
www.sec.gov. The Company assumes no obligation to publicly update
or revise its forward-looking statements as a result of new
information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170623005081/en/
Kadmon Holdings, Inc.Ellen Tremaine, 646-490-2989Investor
Relationsellen.tremaine@kadmon.comorMaeve Conneighton,
212-600-1902maeve@argotpartners.com
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kadmon (NYSE:KDMN)
Historical Stock Chart
From Apr 2023 to Apr 2024